Added to YB: 2026-01-29
Pitch date: 2026-01-27
SLNO [neutral]
Soleno Therapeutics, Inc.
+21.43%
current return
Author Info
No bio for this author
Company Info
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Market Cap
$2.2B
Pitch Price
$43.03
Price Target
80.00 (+53%)
Dividend
N/A
EV/EBITDA
97.60
P/E
105.15
EV/Sales
9.19
Sector
Biotechnology
Category
growth
$SLNO - Fear, not fluid
SLNO (update): Q3/Q4 revenue miss reveals patients downtitrated below Q2 levels due to Scorpion report psychology, not physiology. Model shows even worst-case titration pause couldn't explain low revenues. Clinical data proves edema affects <3% severely vs current population-wide dosing collapse. Psychology-driven weakness temporary; drug's terminal value intact once fear subsides.
Read full article (5 min)